La place des antidiabétiques oraux dans la prise en charge du diabète gestationnel À propos de 81 cas.

Gestational diabetes is a common condition during pregnancy; this condition is associated with significant fetal and neonatal morbidity, as well as considerable cost. The management of gestational diabetes was traditionally based on the rules of hygiene and dietetics and insulin therapy. Oral antidiabetic drugs have been gradually introduced into the proposed therapeutic panel and remain a subject of debate among practitioners. Our work aims to comfort the data of the literature on the use of glibenclamide in the treatment of gestational diabetes. Materials and methods: We carried out a prospective cohort involving two groups of patients with gestational diabetes requiring hypoglycemic treatment, the first group receiving glybenclamide (41 patients) and insulin for the second group (40 patients). Results: Our study showed that these two therapies gave comparable results in terms of glycemic balance and neonatal outcomes without increasing the risk of fetal or perinatal complications. Conclusion: Glibenclamide could replace insulin in the treatment of gestational diabetes while recalling that its use during pregnancy remains off-label (marketing authorization). [ABSTRACT FROM AUTHOR]